Labopharm Inc. today announced that it will host a webcast presentation on Tuesday, December 16, 2008 at 10:00 am during which the Company's senior management team will discuss the product profile, clinical and regulatory progress and the market opportunity for its novel once-daily formulation of trazodone , a serotonin antagonist reuptake inhibitor , for the treatment of major depressive disorder.
Nephros, Inc. , a medical device company focused on developing advanced filtration products for ESRD therapy and water purification, announced today that Mr. James S. Scibetta was appointed to serve as Chairman of its Board of Directors.
- Action Date is July 18, 2009 -LAVAL, QC, Nov. 24 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that its New Drug Application (NDA) for the Company's novel
LAVAL, QC, Nov. 7 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that Rachel R. Selisker has been appointed to the Board of Directors of the Company to fill the
Labopharm Inc. (DDSS) shares were up more than 17% on Thursday after the company announced some encouraging news regarding an appeal to the U.S. Food and Drug Administration for its once-daily pain killer Tramadol.
Labopharm said the FDA did not overturn the prior decision to reject the previous drug trial, but did suggest additional statistical analysis of existing data as a means to potentially satisfy the agency's requirements.
FP Trading Desk submits: Labopharm Inc. (DDSS) shares are down a whopping 50% Friday morning after receiving a second approvable letter from the U.S. Food and Drug Administration [FDA] regarding the company's once-a-day formulation of pain relief drug, Tramadol.
In a nutshell, the FDA didn't approve the once daily version of the drug because it doesn't believe Labopharm has demonstrated the efficacy of it.
LAVAL, QC, Nov. 24 /CNW/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it will host a webcast presentation on Tuesday, December 16, 2008 at 10:00 am (ET) during which the Company ...
Labopharm Inc. (DDSS) announced that its New Drug Application (NDA) for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the ...
(RTTNews) - Labopharm Inc. (DDSS: News ,DDS.TO: News ), a Laval, Canada-based specialty pharmaceutical company, Monday said its New Drug Application or NDA for the novel once-daily formulation of ...
Labopharm, formerly known as Centre de Recherche Appliquee Pharmaceutique (CRAP), is a specialty pharmaceutical company optimizing the performance of existing small molecule drugs using its ...
LAVAL, QC, Nov. 7 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that Rachel R. Selisker has been appointed to the Board of Directors of the Company to fill the ...
- Quarter Highlighted by Submission of NDA for Novel Antidepressant and Steady Global Growth for Once-Daily Tramadol - LAVAL, QC, Nov. 7 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ ...
- Management to discuss third quarter financial results - LAVAL, QC, Oct. 29 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it will host a conference call on ...
<< - Novel Formulation Has Potential to Address Unmet Need in Global Anti-Depressant Market - >> LAVAL, QC, Sept. 22 /CNW/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it has ...
Labopharm Inc. announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for DDS-04A, for the treatment of major depression. Labopharm´s NDA for its ...
NEW YORK (MarketWatch) - IndyMac Bancorp Inc. said Monday said it's considering an initial public offering for its Financial Freedom Senior Funding Corp. as net income at the reverse mortgage unit doubled in the first quarter.
Stocks 
Labopharm said the FDA did not overturn the prior decision to reject the previous drug trial, but did suggest additional statistical analysis of existing data as a means to potentially satisfy the agency's requirements.
